GlassScriptPhysician profile
Jose L Deleon
NPI 1508865320
$1,727.28
in general payments reported to CMS, 2019-2025
16 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $254 · 2021: $23.64 · 2022: $267 · 2023: $154 · 2024: $332 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $371.62 | 2019-2022 | |
| Royal Biologics, INC. | $185.18 | 2024 | |
| Cardiovascular Systems INC. | $150.00 | 2019 | |
| Averitas Pharma INC. | $147.27 | 2024 | Qutenza |
| Amgen INC. | $140.81 | 2025 | Krystexxa |
| Integra Lifesciences Corporation | $138.87 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $121.91 | 2025 | |
| Tactile Systems Technology INC | $108.61 | 2020 | |
| Nevro Corp. | $92.60 | 2023 | Senza |
| Horizon Therapeutics Plc | $87.08 | 2021-2022 | |
| Smith+Nephew, INC. | $59.75 | 2019-2023 | Renasys Go V2 Home |
| Bioventus LLC | $41.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.50 | 2025 | Nuzyra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.48 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.